IDEA Collider: Innovation & Asymmetric Learning in Pharma
Subscribe in ParasocialFree on the App Store for iPhone, iPad and Mac. No subscription needed. Once it is installed, tap this link again and the show is yours. Already have it? Open in Parasocial.
About
IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. The podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace others—and what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * What’s br...
Also on
Recent episodes
- The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II
- Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective and Anti-Inflammatory Strategy
- The Future of Psychedelic Medicine: Clinical Strategy and Scaling Access.
- The Power of the Early Narrative: Sue Wood on Strategic Biotech Positioning
- The Execution Problem: Alex Gray and Jacqueline Poot on Pharma Decision Intelligence.
- The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution
- Scaling TCR-T Therapies: Reagan Jarvis on Non-Viral Gene Editing and Target Mapping
- Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds
- Scaling CAR-T for Autoimmune Disease: Warner Biddle on Kyverna’s Breakthrough Strategy
- Building the Future of Targeted Protein Degradation Medicines with Nello Mainolfi